Article Text
Review
Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety
Abstract
Anti-TNFα therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.
- ANA, antinuclear antibody
- CHF, congestive heart failure
- DMARD, disease modifying antirheumatic drug
- dsDNA, double stranded DNA
- FDA, Federal Drug Administration
- MS, multiple sclerosis
- RA, rheumatoid arthritis
- SLE, systemic lupus erythematosus
- TB, tuberculosis
- TNFα, tumour necrosis factor α
- anti-tumour necrosis factor α
- rheumatoid arthritis
- safety